IL190531A0 - Cannabinoid for the treatment of neuronal damage in diabetic patients - Google Patents

Cannabinoid for the treatment of neuronal damage in diabetic patients

Info

Publication number
IL190531A0
IL190531A0 IL190531A IL19053108A IL190531A0 IL 190531 A0 IL190531 A0 IL 190531A0 IL 190531 A IL190531 A IL 190531A IL 19053108 A IL19053108 A IL 19053108A IL 190531 A0 IL190531 A0 IL 190531A0
Authority
IL
Israel
Prior art keywords
cannabinoid
treatment
diabetic patients
neuronal damage
neuronal
Prior art date
Application number
IL190531A
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL190531A priority Critical patent/IL190531A0/en
Priority to PCT/IL2008/000477 priority patent/WO2008129529A2/en
Publication of IL190531A0 publication Critical patent/IL190531A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
IL190531A 2007-04-19 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients IL190531A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL190531A IL190531A0 (en) 2008-03-31 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients
PCT/IL2008/000477 WO2008129529A2 (en) 2007-04-19 2008-04-06 Cannabinoid for the treatment of neuronal damage in diabetic patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL190531A IL190531A0 (en) 2008-03-31 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients

Publications (1)

Publication Number Publication Date
IL190531A0 true IL190531A0 (en) 2009-02-11

Family

ID=39764920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190531A IL190531A0 (en) 2007-04-19 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients

Country Status (2)

Country Link
IL (1) IL190531A0 (en)
WO (1) WO2008129529A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184848A1 (en) * 2006-07-14 2010-07-22 William Abraham Wine Transdermal formulations of synthetic cannabinoids and nano colloidal silica

Also Published As

Publication number Publication date
WO2008129529A2 (en) 2008-10-30
WO2008129529A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
IL259475A (en) Combination therapy for the treatment of diabetes
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
PL2349388T3 (en) Device and procedure for extracorporeal blood treatment
GB2463797B (en) Skin treating device
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
BRPI1007877A2 (en) "dpp-iv inhibitors for the treatment of diabetes in pediatric patients"
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
ZA200806808B (en) Treatment of stressed patients
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
ZA201005875B (en) Use of interleukin-1 conjugates in the treatment of diabetes
EP2240192A4 (en) Treatment for dermatological conditions
EP2269665A4 (en) Visible medical treatment material
GB2447884B (en) Treatment for skin disease
IL190531A0 (en) Cannabinoid for the treatment of neuronal damage in diabetic patients
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
GB0815179D0 (en) Medication and treatment for infection
GB0700886D0 (en) Medical treatment
GB0816699D0 (en) Monitoring and treating diseases
GB0819037D0 (en) Skin treatment formulation
GB0600817D0 (en) Medical treatment
GB0811492D0 (en) rotating and telesopic patient assist bar(ratpab)
GB0720136D0 (en) Treatment of blood disorded
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0802458D0 (en) Improvements in or relating to medical treatments